Trending
The firm highlighted Capricor's plan to amend its biologics license application from the Hope-3 study for Deramiocel. Capricor reported a second-quarter net loss of $0.70 per share,β¦ [+2454 chars]
Have a news tip or want to get in touch with our editorial team? We're here to help.
Plot C3-C Jaypee Wishtown Sector 129 Noida Uttar Pradesh 201304 India